Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients.

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

PD-1 regulation in immune homeostasis and immunotherapy

Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Expression of Peripheral Blood PD-1 and its Clinical Significance in Patients with Colorectal Cancer

Prognostic value and immunological role of PD-L1 gene in pan-cancer

[Expression of PD-1/PD-L1 in Peripheral Blood Mononuclear Cells in Lung Cancer Patients and Its Biological Significance].

Application of PD-1 Blockade in Cancer Immunotherapy

Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Regulatory mechanisms of PD-1/PD-L1 in cancers

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function

Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy

PD-1 and its ligands are important immune checkpoints in cancer

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation